Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. Company
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Polyphor AG is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.

Number of employees : 52 people.
Sales per Business
20192020Delta
Marcrocylcle Drugs0.01100%14.28100% +142107.17%
CHF in Million
Sales per region
2020
Switzerland14.27100%
Rest of Europe0.010%
CHF in Million
Managers
Name Title Age Since
G÷khan Batur Chief Executive Officer 38 2020
Hernan Levett Chief Financial Officer 45 2019
Daniel Obrecht, Dr. Chief Scientific Officer 65 1996
Frank T. Weber, Dr. Chief Medical & Development Officer 60 2019
Kuno Sommer Chairman 64 2019
Bernard Bollag Independent Director 59 2013
Silvio Inderbitzin, Dr. Independent Director 55 2016
Andreas Walln÷fer, Dr. Vice Chairman 59 2019
Franziska MŘller Head-Human Resources 38 2008
Members of the board
Name Title Age Since
Kuno Sommer Chairman 64 2019
Bernard Bollag Independent Director 59 2013
Silvio Inderbitzin, Dr. Independent Director 55 2016
Andreas Walln÷fer, Dr. Vice Chairman 59 2019
Hugh O'Dowd Director 55 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 12,312,159 10,132,284 82.3% 0 0.0% 82.3%
Shareholders
NameEquities%
Peter Grogg 1,233,350 10.5%
Rudolf Maag 946,525 8.03%
Credit Suisse Asset Management (Schweiz) AG 544,860 4.62%
Daniel Obrecht 196,729 1.67%
ZŘrcher Kantonalbank (Investment Management) 81,928 0.70%
UBS Asset Management Switzerland AG 73,000 0.62%
TOBAM SAS 38,805 0.33%
Giacomo di Nepi 26,031 0.22%
Pictet Asset Management SA 19,282 0.16%
Silvio Inderbitzin 17,744 0.15%
Company contact information
Polyphor AG
Hegenheimermattweg 125
Allschwil, Basel-Landschaft (Basle Country) 4123

Phone : +41.61.567.16.00
Fax : +41.61.567.16.01
Web : http://www.polyphor.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Polyphor AG